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Osteoarthritis (OA) of the knee is the most common type of arthritis and the major
cause of chronic musculoskeletal pain and mobility disability in elderly popula-
tions, and therefore represents a significant burden on health care provision. Well
established risk factors for OA include aging, obesity, and gender (female).
1 The
most recent studies regarding the pathogenesis of OA have shown that the Wnt-β-
catenin signal and the related molecules may regulate the development of OA
through an endochondral ossification process including chondrocyte mutation and
apoptosis.
2
Optimal management of patients with OA of the knee requires a combination of
non-pharmacological and pharmacological modalities of therapy. Recommen-
dations cover the use of 12 non-pharmacological modalities: education and self-
management, regular telephone contact, referral to a physical therapist, aerobic,
muscle strengthening and water-based exercises, weight reduction, walking aids,
knee braces, footwear and insoles, thermal modalities, transcutaneous electrical
nerve stimulation, and acupuncture. Eight recommendations cover pharmacolo-
gical modalities of treatment including acetaminophen, cyclooxygenase-2 (COX-2)
non-selective and selective oral non-steroidal anti-inflammatory drugs (NSAIDs),
topical NSAIDs and capsaicin, intra-articular injections of corticosteroids and
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The purpose of the present study was to discuss the effects of risedronate on osteoarthritis (OA) of the knee by
reviewing the existing literature. The literature was searched with PubMed, with respect to prospective, double-blind,
randomized placebo-controlled trials (RCTs), using the following search terms: risedronate, knee, and osteoarthritis.
Two RCTs met the criteria. A RCT (n = 231) showed that risedronate treatment (15 mg/day) for 1 year improved
symptoms. A larger RCT (n = 1,896) showed that risedronate treatment (5 mg/day, 15 mg/day, 35 mg/week, and 50
mg/week) for 2 years did not improve signs or symptoms, nor did it alter radiological progression. However, a
subanalysis study (n = 477) revealed that patients with marked cartilage loss preserved the structural integrity of
subchondral bone by risedronate treatment (15 mg/day and 50 mg/week). Another subanalysis study (n = 1,885)
revealed that C-terminal crosslinking telopeptide of type II collagen (CTX-II) decreased with risedronate treatment in a
dose-dependent manner, and levels reached after 6 months were associated with radiological progression at 2 years.
The results of these RCTs show that risedronate reduces the marker of cartilage degradation (CTX-II), which could
contribute to attenuation of radiological progression of OA by preserving the structural integrity of subchondral bone.
The review of the literature suggests that higher doses of risedronate (15 mg/day) strongly reduces the marker of
cartilage degradation (CTX-II), which could contribute to attenuation of radiological progression of OA by preserving
the structural integrity of subchondral bone.
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INTRODUCTIONhyaluronates, glucosamine and/or chondroitin sulphate for
symptom relief; glucosamine sulphate, chondroitin sulphate
and diacerein for possible structure-modifying effects and
the use of opioid analgesics for the treatment of refractory
pain.
3 Basically, however, weight loss, physical therapy, and
activity are important components of treatment.
Recently, studies using animal models of OA have shown
that bisphosphonates are potentially therapeutic agents for
disease modification in OA.
4-6 In the Duncan-Hartley guinea
pig mode of spontaneous OA (the best-characterized mo-
del of primary non-traumatic OA
4), the bisphosphonate,
risedronate was shown to slow disease progression as
measured by cartilage lesion size, severity, and osteophyte
size, with a maximal effect of disease suppression of 30-
40%.
7 There are several prospective, double-blind, rando-
mized placebo-controlled trials (RCTs) reporting on the
effects of risedronate on symptoms, function, and progre-
ssion of OA in patients with OA of the knee.
8-11 Thus, rise-
dronate could be a new candidate for the treatment of
OA.
12 The purpose of the present study was to discuss the
effect of risedronate on OA of the knee by reviewing the
existing literature.
Approaches for Determining the Effects of Risedronate
on Knee OA
Prospective, double-blind RCTs on the effect of risedro-
nate on OA in patients with knee OA were identified
through PubMed, using the following search terms: risedro-
nate, knee, and osteoarthritis. The literature search was
conducted for English publications on RCTs. The effects
of risedronate on symptoms, function, and progression of




Two RCTs (four studies) met the criteria regarding the
effects of risedronate on OA in patients with knee OA.
8-11
Table 1 shows the details of the identified four studies. The
British study of risedronate in structure and symptoms of
knee OA (BRISK) tested the efficacy and safety of rise-
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MATERIALS AND METHODS
Table 1.Studies That Met the Criteria
Investigators Study subjects Groups n Study End-points (year reported) period
Patients (40 - 80 yrs of age) 
Joint space width, 
Spector (2005)
8 with mild to moderate
Risedronate (5 mg/day) 96 WOMAC OA index,
(BRISK) medial compartment
Risedronate (15 mg/day) 90 1 yr PGA score, use of
knee  OA
Placebo 98 walking aids, bone
and cartilage markers
Patients (40 - 80 yrs of age)
Risedronate (5 mg/day) 628
WOMAC OA index,
Bingham (2006)
9 with medial compartment
Risedronate (15 mg/day) 609
PGA score, 
(KOSTAR) knee OA and 2 - 4 mm of 
Risedronate (35 mg/wk) 310 2 yrs
radiographic
joint space width
Risedronate (50 mg/wk) 314
progression of OA
Placebo 622
Patients (40 - 80 yrs of age) 
Risedronate (5 mg/day) 310
Buckland-Wright  with mild to medial 
Risedronate (15 mg/day) 305 Subchondral bone
(2007)
10* compartment knee OA 
Risedronate (50 mg/wk) 314
2 yrs
structure
(KOSTAR) (a part of Bingham’s
Placebo 313
study subjects were used)
Patients (40 - 80 yrs of age)
Risedronate (5 mg/day) In total, 
with mild to medial 
Risedronate (15 mg/day) 1885
Radiographic
Garnero (2008)
11* compartment knee  OA and 
Risedronate (35 mg/wk) (available 2 yrs
progression
(KOSTAR) 2 - 4 mm of  joint space 
Risedronate (50 mg/wk) for 
of OA, bone and
width (A part of Bingham’s
Placebo analysis)
cartilage markers
study subjects were used)
OA, osteoarthritis; WOMAC, Western Ontario and McMaster Universities; PGA, patient global assessment; BRISK, The British Study of Risedronate in Structure 
and Symptoms of Knee OA; KOSTAR, The Knee OA Structural Arthritis. 
*Subanalysis of a previous randomized controlled trial (KOSTAR) conducted by Bingham, et al.
9dronate in patients with knee OA. The Knee OA Structural
Arthritis (KOSTAR) study of North America and the
European Union, which is the largest study to date inves-
tigating a potential structure-modifying OA drug, tested
the efficacy of risedronate in providing symptom relief and
slowing disease progression in patients with knee OA.
Studies of Backland-Wright, et al.
10 and Garnero, et al.
11
were subanalyses of a previous RCT (KOSTAR) con-
ducted by Bingham, et al.
9 Finally, four studies in two
RCTs were identified. 
In four studies from two RCTs, the study subjects
included patients (40-80 years of age) with mild to medial
compartment knee OA. OA was diagnosed according to
the clinical and radiological criteria of the American College
of Rheumatology.
13 The doses of risedronate were 5
mg/day, 15 mg/day, 35 mg/week, and 50 mg/week. The
study periods were 1-2 years. The numbers of study
subjects enrolled were 284-2,483, and those analyzed were
231-1,896. The follow-up rates were 37.1-83.3%. The out-
comes of RCTs were measured by Western Ontario and
McMaster Universities (WOMAC) OA index (total, pain,
function, and stiffness),
14 patient global assessment (PGA)
scores, use of walking aids, subchondral bone structure,
radiographic progression of OA, bone and cartilage markers.
WOMAC measurements were collected on a 100-mm
visual analog scale (VAS). For assessment of the PGA
score, patients answered the following question using a
VAS: “Considering all the ways your OA affects you, how
have you been in the last 48 hours?” Patients marked
values on a scale from 0 to 100 mm.
Effects of risedronate on knee OA
Table 2 summarizes the outcomes of four studies in two
RCTs. A RCT (n = 231, study period 1 year) by Spector,
et al.
8 showed that risedronate (15 mg/day) reduced urinary
levels of C-terminal crosslinking telopeptide of type II
collagen (CTX-II) (Fig. 1) and N-terminal crosslinking
telopeptide of type I collagen (NTX-I) in a dose-dependent
manner, improved PGA scores but not WOMAC scores,
reduced the proportion of patients who used walking aids,
but did not attenuate joint space narrowing. Thus, rise-
dronate (15 mg/day) reduced markers of cartilage degra-
dation and bone resorption and improved symptoms of OA.
A larger RCT (n = 1,896, study period 2 years) by
Bingham, et al.
9 showed that risedronate at any doses (5
mg/day, 15 mg/day, 35 mg/week, and 50 mg/week)
reduced urinary levels of CTX-II and NTX-I, but did not
improve WOMAC scores, PGA scores, average number of
days, and number of pills of analgesic medication taken
per week, joint space width, and osteophyte development.
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(year reported) completed the trial
Spector  Risedronate (5 mg/day) 80 (83.3) Risedronate (15 mg/day) reduced markers of  
(2005)
8 Risedronate (15 mg/day) 71 (78.9) cartilage degradation and bone resorption and
(BRISK) Placebo 80 (81.6) improved symptoms 
Risedronate (5 mg/day) 493 (78.5)
Risedronate did not improve signs or symptoms
Bingham Risedronate (15 mg/day) 466 (76.5)
of OA, nor did it alter progression of OA, although
(2006)
9 Risedronate (35 mg/wk) 244 (78.7)
a reduction in the level of a marker of cartilage was
(KOSTAR) Risedronate (50 mg/wk) 218 (69.4)
observed
Placebo 475 (76.4)
Patients with marked cartilage loss (joint space
Buckland-Wright
Risedronate (5 mg/day) 124 (38.3) narrowing ≥0.6 mm) receiving risedronate
(2007)
10*
Risedronate (15 mg/day) 115 (37.1) (15 mg/day) retained vertical trabecular structure, 
(KOSTAR)
Risedronate (50 mg/wk) 118 (38.7) and those receiving risedronate (50 mg/wk) increased 
Placebo 120 (38.2) vertical trabecular number, thereby preserving the 
structural integrity of subchondral bone
Risedronate (5 mg/day)
In total, CTX-II decreased with risedronate treatment in 
Garnero  Risedronate (15 mg/day)
1,885  a dose-dependent manner, and levels reached after
(2008)
11* Risedronate (35 mg/wk)
(available  6 months were associated with radiological
(KOSTAR) Risedronate (50 mg/wk)
for analysis) progression at 2 yrs
Placebo
OA, osteoarthritis; WOMAC, Western Ontario and McMaster Universities; PGA, patient global assessment; CTX-II: C-terminal cross-linked telopeptide of type 
II collagen; BRISK, The British Study of Risedronate in Structure and Symptoms of Knee OA; KOSTAR, The Knee OA Structural Arthritis. 
*Subanalysis of a previous randomized controlled trial (KOSTAR) conducted by Bingham, et al.
9Thus, risedronate did not improve signs or symptoms of
OA, nor did it alter progression of OA, although a reduc-
tion in the level of a marker of cartilage was observed.
A subanalysis study (the North America arm, n = 477) by
Buckland-Wright, et al.
10 used computed method of fractal
signature analysis (FSA) to quantify longitudinal changes
separately in horizontal and vertical trabeculae in the
region of interest (three-fourth width of tibial compartment
×6 mm height) in the medial compartment. It was revealed
that patients with marked cartilage loss (joint space
narrowing ≥ 0.6 mm) receiving risedronate (15 mg/day)
retained vertical trabecular structure, and those receiving
risedronate (50 mg/week) increased vertical trabecular
numbers, thereby preserving the structural integrity of
subchondral bone. Thus, higher doses of risedronate (15
mg/day and 50 mg/week) inhibited trabecular bone loss in
the subchondral region of the diseased medial compart-
ment of the tibia.
Another subanalysis study by Garnero, et al.
11 (the North
America and European Union arms, n = 1,885) revealed
that urinary levels of CTX-II and NTX-I decreased with
risedronate treatment in a dose-dependent manner (Fig. 2).
In particular, higher doses of risedronate (15 mg/day)
strongly reduced urinary levels of CTX-II and NTX-I.
Patients who had CTX-II levels returned to low levels at 6
months (high/low group in Table 3) had a lower risk of
radiographic progression of OA at 24 months than patients
whose CTX-II levels were increased both at baseline and 6
months (high/high group in Table 3) (odds ratio 0.57, 95%
confidence interval 0.39-0.85) after adjustment for body
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Fig. 1. Changes in urinary CTX-II levels after treatment with placebo or
risedronate in patients with Knee OA. OA, osteoarthritis; CTX, C-terminal
crosslinking of type II collagen. *p < 0.05 vs. placebo,   **p < 0.001 vs. placebo.
Fig. 2. Changes in urinary NTX-I and CTX-II levels in patients with knee OA treated with placebo or risedronate. The graphs show the median and the confidence
interval limits of the percentage change from baseline of NTX-I (left) and CTX-II (right) in the European (A) or North American (B) study. OA, osteoarthritis; NTX, N-
terminal crosslinking of type I collagen; CTX, C-terminal crosslinking of type II collagen.
B
Amass index, gender, WOMAC pain, hip OA, knee crepitus
at baseline, baseline joint space width, and treatment allo-
cation. The lower risk of progression of OA was observed
in patients who had low CTX-II levels both at baseline and
6 months (low/low group in Table 3) (odds ratio 0.36, 95%
confidence interval 0.21-0.63). Thus, measurements of
urinary CTX-II prior to initiating treatment with risedro-
nate and 6 months after the start of therapy provide useful
information with respect to the radiological prognosis of
patients with knee OA.
The results of these RCTs show that higher dose of
risedronate (15 mg/day) strongly reduces the marker of
cartilage degradation (CTX-II), which could contribute to
attenuation of radiological progression of OA by preserv-
ing the structural integrity of subchondral bone. However,
the effects of risedronate on symptoms and functions of
knee OA were inconsistent.
Adverse events of risedronate
The number of dropouts and withdrawals was similar
across groups in two RCTs. Adverse events were catego-
rized using the Coding Symbols for Thesaurus of Adverse
Reaction Terms (COSTAT) coding dictionary. The inci-
dence of side effects including upper gastrointestinal
adverse events did not differ significantly among subjects
treated with risedronate at any doses and placebo. No
severe adverse event was observed in any RCTs. All doses
of risedronate treatment used in RCTs were well tolerated,
and risedronate was confirmed to be safe in patients with
knee OA.
Treatment of knee OA ought to be conducted in accor-
dance with the principles of evidence-based medicine
(EBM). EBM incorporates information derived from the
highest-quality investigations with clinical judgment and
patient values, to allow optimal clinical management. Avail-
able clinical evidence has been classified hierarchically
into various levels, with strictly conducted systematic re-
views representing the highest level, followed by RCTs or
meta-analyses of RCTs, which have long been considered
as the “gold standard” in the context of clinical investiga-
tions.
15 Thus, the present study was conducted as a review
of the literature, especially prospective, double-blind
RCTs, to discuss the effects of risedronate on knee OA.
It is known that joint space narrowing, sclerosis of the
subchondral bone, and presence of osteophyte are typical
structural features of knee OA. Thus, both articular carti-
lage and subchondral bone were considered to be involved
in the pathogenesis of knee OA. However, recent evidence
has shown that increased local bone turnover, decreased
bone mineral content and stiffness, trabecular bone loss
have been observed in the subchondral bone structure of
knee OA,
4,16,17 and therefore subchondral bone abnor-
malities might be a major factor in disease progression.
Progressive thickening and flattering of the subchondral
cortical plate could produce a “stress shielding” effect,
resulting in localized trabecular bone loss as well as increas-
ed bone turnover in the subchondral bone.
18-21 Actually,
levels of bone turnover markers have been reported to be
higher in patients with progressive knee OA similarly to
postmenopausal women with osteoporosis.
22 Patients with
progressive knee OA may have a higher bone turnover
compared with milder knee OA, because urinary levels of
CTX-II are correlated with the progression of knee OA.
11
Thus, subchondral bone is an important therapeutic OA
target, and could be modified in patients with progressive
knee OA by anti-resorptive agents such as bisphosp-
honates. The main outcomes of four studies in RCTs were
not only WOMAC OA index and PGA score, but also
radiographic progression of OA, subchondral bone struc-
ture, and bone and cartilage markers.
Modulating subchcondral bone turnover by bisphos-
phonates has become an attractive approach as a potential
structure modifying anti-OA drug target. Bisphosphonates
are anti-resorptive compounds that regulate bone turnover
Jun Iwamoto, et al.
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DISCUSSION
Table 3.Urinary CTX-II Levels at Baseline and 6 Months for Predicting 24-Month Radiological Progression
Urinary CTX-II levels
Mean ± SE of change in joint Radiological progression
�
(baseline / 6 months*)
space narrowing at 24 months at 24 months
Absolute change (mm) % change from baseline Progressor (%) Relative risk (95% CI)
�
High / High (n = 1,152) - 0.121 ± 0.015 - 4.2 ± 0.5 15 1.0 (reference)
High / Low (n = 372) - 0.088 ± 0.023 - 2.9 ± 0.8 11 0.57 (0.39 - 0.85)
Low / High (n = 120) - 0.108 ± 0.039 - 4.5 ± 1.5 13 0.77 (0.43 - 1.36)
Low / Low (n = 241) - 0.041 ± 0.024 -1.6 ± 0.9 6 0.36 (0.21 - 0.63)
OA, osteoarthritis; CTX, C-terminal crosslinking of type II collagen; WOMAC, Western Ontario and McMaster Universities; CI, confidence interval.
*Baseline and 6 month cut-off values of CTX-II at 150 nmol/mmol to separate low and high levels.
�Progression was defined as a joint space narrowing ≥0.6 mm at any post baseline visit.
�Relative risks were adjusted for body mass index, WOMAC pain, hip OA, knee crepitus at baseline,  baseline joint space narrowing and treatment allocation.through suppression of osteoclastic activity. The effect of
risedronate on bone turnover helps to preserve the trab-
cular architecture and thus improve bone strength in hu-
mans.
23 The results of the present review of the literature
show that higher doses of risedronate (15 mg/day) strongly
reduce the marker of cartilage degradation (CTX-II),
which could contribute to attenuation of radiological pro-
gression of OA by preserving the structural integrity of
subchondral bone. However, clinical relevance of suppres-
sion of bone turnover and preservation of the structural
integrity of subchondral bone by risedronate treatment
remains uncertain.
Both RCTs showed risedronate treatment reduced urinary
levels of CTX-II and NTX-I,
8,9 and a subanalysis study of
the RCT (KOSTAR) by Garnero, et al.
11 revealed that
urinary levels of CTX-II, but not NTX-I, reached after 6
months of risedronate treatment were associated with
radiological progression of knee OA at 24 months. CTX-II
is a marker of cartilage degradation, while radiological
progression of knee OA might be associated with subchon-
dral bone structure. The association of urinary CTX-II and
progression of knee OA could be explained by the studies
suggesting that CTX-II is not only released from the
surface of the cartilage, but also from the bone to cartilage
interface region within the calcified region.
24,25 The rapid
reduction in urinary levels of CTX-II might be attributable
to decreases in subchondral bone turnover and articular
and/or calcified cartilage degradation.
11
The effects of risedronate on symptoms and functions of
knee OA were inconsistent when WOMAC OA index and
PGA scores were used as end-points. In a subanalysis
study of the RCT (BRISK) by Buckland-Wright, et al.,
10
there was a beneficial effect of higher doses of risedronate
(15 mg/day and 50 mg/week) on subchondral bone struc-
ture, but this was not correlated with a concomitant treat-
ment effect for signs and symptoms of knee OA. The
radiological severity of knee OA is not always correlated
with signs and symptoms, because clinically, various
factors including quadriceps muscle weakness could
contribute to signs and symptoms. Thus, additional treat-
ments to risedronate may be needed to improve WOMAC
OA index and PGA scores in terms of symptoms and
functions in patients with knee OA.
Like risedronate, other bisphosphonates such as alend-
ronate, zoledronate, and neridronate may have the potential
to be efficacious for radiological progression of knee OA,
26
although there are no reports of RCTs in patients with knee
OA. Recently, Neogi, et al.
27 conducted a secondary analysis
of patients randomly selected from the Fracture Interven-
tion Trial (FIT), and demonstrated a small reduction in
spinal osteophyte progression in those patients randomized
to receive alendronate compared with placebo. Bruyere, et
al.
28 also conducted a post-hoc analysis of pooled data from
the Spinal Osteoporosis Therapeutic Intervention (SOTI)
and TReatment Of Peripheral OSteoporosis (TROPOS)
trials, and showed that strontium ranelate could reduce the
progression of the radiographic features of spinal OA and
back pain in women with osteoporosis and prevalent spinal
OA. Thus, alendronate and strontium ranelate could be a
potential interest in OA. However, further studies are
required to establish the effect of those bisphosphonates
and strontium ranelate on knee OA.
There are critical limitations in the present review study.
First, the number of RCTs was so small that meta-analysis
or systematic review was not possible. Second, the propor-
tion of patients included in RCTs who had significant
progression of joint space narrowing was so small that a
longer-period of observation or subjects with more risk
factors for disease progression might be needed to deter-
mine the effect of risedronate on the progression of knee
OA. Meta-analysis or systematic review studies analyzing
RCTs with longer period of observation in patients with
more risk factors for disease progression including further
RCTs are needed to establish the efficacy of risedronate
for symptom, function, and progression of knee OA.
In conclusion, the review of the literature suggests that
higher doses of risedronate (15 mg/day) strongly reduces
the marker of cartilage degradation (CTX-II), which could
contribute to attenuation of radiological progression of OA
by preserving the structural integrity of subchondral bone.
However, meta-analysis or systematic review studies anal-
yzing RCTs including further RCTs are required to esta-
blish the efficacy of risedronate for symptoms, function,
and progression of knee OA.
We have no funding sources from any pharmaceutical
company. We have no involvement of any pharmaceutical
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